Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia

Journal of Psychiatric Research

Volumn 51, Issue 1, 2014, Pages 49-59

  Villar Menéndez, Izaskun ^a   Díaz Sánchez, Sara ^b   Blanch, Marta ^a   Albasanz, José Luis ^b   Pereira Veiga, Thais ^a   Monje, Alfonso ^c,f   Planchat, Luis Maria ^c   Ferrer, Isidre ^a,d,e   Martín, Mairena ^b   Barrachina, Marta ^a,e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^f PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

5 Methylcytosine; Adenosine A(2A) receptor; ADORA2A; Motor disturbances; PANSS; Postmortem; Putamen; Schizophrenia

Indexed keywords

5 METHYLCYTOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; BETA ACTIN; BISULFITE; DNA;

5' UNTRANSLATED REGION; ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; ARTICLE; AUTOPSY; BRAIN LEVEL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PUTAMEN; RADIOASSAY; REAL TIME POLYMERASE CHAIN REACTION; REDUCTION; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; VERY ELDERLY; WESTERN BLOTTING;

5-METHYLCYTOSINE; ADENOSINE A(2A) RECEPTOR; ADORA2A; MOTOR DISTURBANCES; PANSS; POSTMORTEM; PUTAMEN; SCHIZOPHRENIA;

ACTINS; ADENOSINE A1 RECEPTOR ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CELL MEMBRANE; DNA METHYLATION; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POSTMORTEM CHANGES; PSYCHIATRIC STATUS RATING SCALES; PUTAMEN; RECEPTOR, ADENOSINE A2A; SCHIZOPHRENIA; TRIAZINES; TRIAZOLES; TRITIUM; XANTHINES;

EID: 84893907889     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.12.013     Document Type: Article

References (54)

1. Abdolmaleky H.M., Cheng K.H., Russo A., Smith C.L., Faraone S.V., Wilcox M., et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet Neuropsychiatr Genet 2005, 134B:60-66.
2. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. JClin Pharm Ther 2000, 25:131-137.
3. Akhondzadeh S., Safarcherati A., Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:253-259.
4. Albasanz J.L., Perez S., Barrachina M., Ferrer I., Martín M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 2008, 18:211-219.
5. Boison D., Singer P., Shen H.Y., Feldon J., Yee B.K. Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy. Neuropharmacol 2012, 62:1527-1543.
6. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
7. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112:389-404.
8. Brunstein M.G., Ghisolfi E.S., Ramos F.L., Lara D.R. Aclinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. JClin Psychiatry 2005, 66:213-219.
9. Brunstein M.G., Silveira E.M., Chaves L.S., Machado H., Schenkel O., Belmonte-de-Abreu P., et al. Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment. Neurosci Lett 2007, 414:61-64.
10. Buchanan R.W., Heinrichs D.W. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 1989, 27:335-350.
11. Buira S.P., Dentesano G., Albasanz J.L., Moreno J., Martín M., Ferrer I., et al. DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. JNeurochem 2010, 115:283-295.
12. Buira S.P., Albasanz J.L., Dentesano G., Moreno J., Martín M., Ferrer I., et al. DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. JNeurochem 2010, 112:1273-1285.
13. Deckert J., Nöthen M.M., Bryant S.P., Schuffenhauer S., Schofield P.R., Spurr N.K., et al. Mapping of the human adenosine A2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet 1997, 99:326-328.
14. Deckert J., Brenner M., Durany N., Zöchling R., Paulus W., Ransmayr G., et al. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 2003, 14:313-316.
15. Dempster E.L., Pidsley R., Schalkwyk L.C., Owens S., Georgiades A., Kane F., et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 2011, 20:4786-4796.
16. Dickerson F.B., Stallings C.R., Origoni A.E., Sullens A., Khushalani S., Sandson N., et al. Adouble-blind trial of adjunctive allopurinol for schizophrenia. Schizophr Res 2009, 109:66-69.
17. Dixon D.A., Fenix L.A., Kim D.M., Raffa R.B. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother 1999, 33:480-488.
18. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacol Berl 1997, 133:107-120.
19. Ferrer I., Martinez A., Boluda S., Parchi P., Barrachina M. Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 2008, 9:181-194.
20. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012, 97:38-51.
21. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
22. Gavin D.P., Akbarian S. Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiol Dis 2012, 46:255-262.
23. Gotoh L., Mitsuyasu H., Kobayashi Y., Oribe N., Takata A., Ninomiya H., et al. Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatr Genet 2009, 19:328-335.
24. Grayson D.R., Chen Y., Dong E., Kundakovic M., Guidotti A. From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics 2009, 4:144-149.
25. Grayson D.R., Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013, 38:138-166.
26. Guidotti A., Dong E., Kundakovic M., Satta R., Grayson D.R., Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009, 30:55-60.
27. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU assessment manual of psychopharmacology 1976, 534-537. US Department of Health, Education and Welfare Publication (ADM) 76-338, Rockville: Md, National Institute of Mental Health.
28. Hohoff C., Mullings E.L., Heatherley S.V., Freitag C.M., Neumann L.C., Domschke K., et al. Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. JPsychiatr Res 2010, 44:930-937.
29. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009, 35:549-562.
30. 2A antagonists, and Parkinson's disease. Park Rel Disord 2009, 15:406-413.
31. Jones P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13:484-492.
32. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
33. Kozielska M., Pilla Reddy V., Johnson M., de Ridder F., Vermeulen A., Liu J., et al. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. Schizophr Res 2013, 146:53-58.
34. Kundakovic M., Chen Y., Costa E., Grayson D.R. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 2007, 71:644-653.
35. Kurumaji A., Toru M. An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res 1998, 808:320-323.
36. Lara D.R., Souza D.O. Schizophrenia: a purinergic hypothesis. Med Hypotheses 2000, 54:157-166.
37. Levenson J.M. DNA (cytosine-5) methyltransferase inhibitors: a potential therapeutic agent for schizophrenia. Mol Pharmacol 2007, 71:635-637.
38. Mill J., Tang T., Kaminsky Z., Khare T., Yazdanpanah S., Bouchard L., et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008, 82:696-711.
39. Mishina M., Kimura Y., Naganawa M., Ishii K., Oda K., Sakata M., et al. Differential effects of age on human striatal adenosine A1 and A(2A) receptors. Synapse 2012, 66:832-839.
40. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009, 39:1065-1076.
41. Parsons B., Togasaki D.M., Kassir S., Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. JNeurochem 1995, 65:2057-2064.
42. Peralta V., Cuesta M.J. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001, 49:269-285.
43. Peralta V., Campos M.S., De Jalón E.G., Cuesta M.J. Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders. Mov Disord 2010, 25:1068-1076.
44. Peralta V., Moreno-Izco L., Sanchez-Torres A., García de Jalón E., Campos M.S., Cuesta M.J. Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr Bull 2012 Dec 18, Epub.
45. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
46. Schiffmann S.N., Fisone G., Moresco R., Cunha R.A., Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007, 83:277-292.
47. Shen H.Y., Singer P., Lytle N., Wei C.J., Lan J.Q., Williams-Karnesky R.L., et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. JClin Invest 2012, 122:2567-2577.
48. Simpson G.M., Angus J.W. Arating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
49. Tochigi M., Iwamoto K., Bundo M., Komori A., Sasaki T., Kato N., et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry 2008, 63:530-533.
50. Veldic M., Caruncho H.J., Liu W.S., Davis J., Satta R., Grayson D.R., et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A 2004, 101:348-353.
51. 2AR levels in Huntington's disease. Neuromolecular Med 2013, 15:295-309.
52. Wonodi I., Gopinath H.V., Liu J., Adami H., Hong L.E., Allen-Emerson R., et al. Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacol Berl 2011, 218:341-345.
53. Zhang J., Abdallah C.G., Wang J., Wan X., Liang C., Jiang L., et al. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Res 2012, 200:126-132.
54. Zhubi A., Veldic M., Puri N.V., Kadriu B., Caruncho H., Loza I., et al. An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 2009, 111:115-122.